NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapeutics for unmet medical needs in diabetic neuropathy and Alzheimer's disease. The company's lead candidate, NB-01, is a Phase III-ready drug derived from natural sources that has demonstrated promising efficacy and safety in treating diabetic neuropathic pain, addressing both the symptoms and underlying mechanisms of the condition. Approximately 40 to 50 percent of patients with diabetic peripheral neuropathy experience neuropathic pain, yet existing treatments provide limited relief and have significant adverse effects. NeuroBo is also advancing NB-02, its lead Alzheimer’s drug, which is currently in the IND-enabling stage. This drug has been thoroughly studied in preclinical models, targeting key pathways involved in Alzheimer's disease. With the growing prevalence of these conditions among aging populations, NeuroBo Pharmaceuticals aims to provide effective solutions that not only manage symptoms but also modify the diseases themselves.
Top Stages
2 past transactions
ANA Therapeutics
Acquisition in 2020
ANA Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions for the treatment of coronavirus, specifically COVID-19. Founded in 2020 and based in Foster City, California, the company is advancing a proprietary formulation of niclosamide, marketed under the name ANA001. This drug is delivered in capsule form and is currently undergoing human clinical trials. The objective of ANA Therapeutics is to provide effective treatment options for medical practitioners to help patients affected by the coronavirus pandemic, thereby aiming to contribute to the global response to this public health crisis.
Gemphire Therapeutics
Acquisition in 2019
Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is known for its development of gemcabene, a novel oral medication aimed at lowering LDL cholesterol levels in patients who have not achieved their lipid-lowering goals, particularly those on maximally tolerated statin therapy. Gemphire has conducted multiple Phase IIb clinical trials for gemcabene, targeting conditions such as homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, and severe hypertriglyceridemia. Founded in 2008 and headquartered in Livonia, Michigan, Gemphire Therapeutics is dedicated to addressing the needs of patients with cardiometabolic disorders. The company was acquired by NeuroBo Pharmaceuticals in a reverse merger transaction in December 2019.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.